CASTLE BIOSCIENCES INC (CSTL) Stock News

USA - NASDAQ:CSTL - US14843C1053 - Common Stock

33.04 USD

-0.51 (-1.52%)

Last: 11/7/2025, 8:00:01 PM

33.04 USD

0 (0%)

After Hours: 11/7/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CSTL Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: SciBase

News Image

SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement of SEK 20 million

3 days ago - By: Zacks Investment Research

Recent Price Trend in Castle Biosciences (CSTL) is Your Friend, Here's Why

3 days ago - By: Benzinga

Why Castle Biosciences' Rally Might Just Be Getting Started

3 days ago - By: Benzinga - Mentions: SMCI ADM AMD AWK ...

AMD To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday

5 days ago - By: Zacks Investment Research - Mentions: ADCT

Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Tops Revenue Estimates

5 days ago - By: Castle Biosciences, Inc.

Castle Biosciences Reports Third Quarter 2025 Results

11 days ago - By: Castle Biosciences, Inc.

Castle Biosciences to Participate in Upcoming Investor Conferences

2 months ago - By: SciBase

News Image

SciBase receives initial order for clinical study from Castle Biosciences

5 days ago - By: Castle Biosciences, Inc.

Castle Biosciences Reports Third Quarter 2025 Results

5 days ago - By: Castle Biosciences, Inc.

Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

5 days ago - By: Castle Biosciences, Inc.

Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

9 days ago - By: Zacks Investment Research - Mentions: RDNT RAIL AVO

Forget Profit, Pick These 4 Stocks With Increasing Cash Flows

11 days ago - By: Castle Biosciences, Inc.

Castle Biosciences to Participate in Upcoming Investor Conferences

13 days ago - By: Castle Biosciences, Inc.

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus

13 days ago - By: Castle Biosciences, Inc.

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus

15 days ago - By: Castle Biosciences, Inc.

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

15 days ago - By: Castle Biosciences, Inc.

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

16 days ago - By: Zacks Investment Research - Mentions: ALKS AVDL CMMB

ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition

16 days ago - By: Zacks Investment Research

How Much Upside is Left in Castle Biosciences (CSTL)? Wall Street Analysts Think 50.08%

a month ago - By: Castle Biosciences, Inc.

Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025

a month ago - By: Castle Biosciences, Inc.

Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025

a month ago - By: Castle Biosciences, Inc.

Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine

a month ago - By: Castle Biosciences, Inc.

Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine

2 months ago - By: Castle Biosciences, Inc.

Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award

2 months ago - By: Castle Biosciences, Inc.

Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award

2 months ago - By: Castle Biosciences, Inc.

Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025

2 months ago - By: Castle Biosciences, Inc.

Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025

2 months ago - By: Castle Biosciences, Inc.

New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

2 months ago - By: Castle Biosciences, Inc.

New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

3 months ago - By: Castle Biosciences, Inc.

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

3 months ago - By: Castle Biosciences, Inc.

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

3 months ago - By: Castle Biosciences, Inc.

Castle Biosciences to Participate in Upcoming Investor Conferences

3 months ago - By: Castle Biosciences, Inc.

Castle Biosciences to Participate in Upcoming Investor Conferences